Drug Trial Radar · NCT02362503
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
371
Actual
Start
Feb 23, 2015
Primary completion
Aug 18, 2016
Study completion Oct 22, 2026
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Conditions
- HIV Infections
Interventions
BMS-663068Drug
BMS-663068
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized CohortTime frame: Day 1 and Day 8
Locations
139 sites in 25 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Wilton Manors, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Southfield, Michigan
GSK Investigational Site
Hillsborough, New Jersey
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
Manhasset, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Tulsa, Oklahoma
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Bellaire, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Buenos Aires, Argentina
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.